Wales winger Louis Rees-Zammit has signed a long-term contract extension with Bristol Bears. The 24-year-old Rees-Zammit ...
ReScript 12.0 has launched, marking a milestone in modernizing the language with a rewritten build system, improved ...
Billy Strings is opening up about the unexpected death of his mother, Debra Apostal, which happened in June. Strings — whose legal name is William Lee Apostal — says his mom wasn't sick leading up to ...
Billy Strings revealed that he wants to set his late mother’s poetry to music for a potential new album during an extensive interview about drug use and addiction on the Dopey podcast. Strings’ mother ...
The average one-year price target for Replimune Group (NasdaqGS:REPL) has been revised to $10.84 / share. This is an increase of 48.75% from the prior estimate of $7.29 dated September 27, 2025. The ...
Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
Hamza is a gaming enthusiast and a Writing Specialist from Pakistan. A firm believer in Keyboard/Mouse supremacy, he will play Tekken with WASD if you let him. He has been writing about games since ...
Singer-songwriter Billy Strings says his guitar has been his best friend for as long as he can remember. "I slept with my guitar when I was 4 or 5 years old," he says. "I'd put it right under the ...
LOS ANGELES--(BUSINESS WIRE)--The DJS Law Group reminds investors of a class action lawsuit against Replimune Group, Inc. (“Replimune” or “the Company”) (NASDAQ: REPL) violations of §§10(b) and 20(a) ...
FARGO — Billy Strings may not exactly be a household name, but in homes tuned into bluegrass he certainly is. The 32-year-old returns to Fargo-Moorhead on Tuesday and is close to selling out the ...
Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, ...
Despite a sharp drop in the previous session following the FDA rejection of its skin cancer drug RP1, Replimune (NASDAQ:REPL) shares bounced back on Wednesday even as multiple Wall Street analysts ...